Nocturia is an independent predictor of abdominal aortic calcification in women : results from the National Health and Nutrition Examination Survey

Nocturia is generally considered a urological condition, but may be an indicator of cardiovascular disease, as prior studies have found associations with cardiovascular risk factors as well as clinical and subclinical markers of coronary artery disease. This study aimed to explore potential associations between nocturia and abdominal aortic calcification (AAC). We analyzed 2013-2014 National Health and Nutrition Examination Survey dual energy x-ray absorptiometry-derived AAC data and concurrent interview data on kidney conditions from respondents aged 40-80 years. AAC was defined as a score >= 1 on the 24-point semi-quantitative AAC scale. Nocturia was defined as an average of >= 2 voids per night. Three incremental multivariate logistic regression models controlling for (1) age, (2) sex, race, and BMI, and (3) hypertension, diabetes mellitus, and smoking history were used to determine whether nocturia predicted AAC. These models were and modified to exclude age and/or sex to perform age- and/or sex-specific sub-analyses, respectively. Complete data were available from 2,945 participants (29.1% AAC, 31.4% nocturia). On univariate analysis, the association between nocturia and AAC was significant in women (OR 1.77 [95% CI 1.37-2.29], p < 0.001), but not in men (1.14 [0.74-1.76], p = 0.531). Multivariate analysis showed nocturia was an independent predictor of AAC in women in Models I-II (ORs 1.49-1.58, p <= 0.032) but not Model III (1.37 [0.90-2.09], p = 0.133). Stratification by age revealed a strong univariate association among women aged 50-59 (3.88 [1.97-7.61], p < 0.001), which persisted across all multivariate models (ORs 4.05-4.41, p <= 0.001). The presence of nocturia is an important clue of AAC in women, especially those middle-aged

Additional file 2 of A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Additional file 2: Figure S2. Creation of the 74bbz mutant clones. A GFP+ cells of the 74bbz mutants and parent CAR expressing Jurkat cells were sorted at the same intensity by flow cytometry. B An immunoblot of CD3ζ to show the expressing of parent, 543, 5311, 42105-74bbz clones. Endogenous CD3ζ was detected at 15 kDa while the chimeric CD3ζ on CAR was detected at 55 kDa. C CD74-ECD-Fc fusion protein was stained by Coomassie blue staining

Additional file 1 of A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Additional file 1: Figure S1. In silico modeling of CD74-anti-CD74 scFV interaction. A Best generated models of CD74-anti-CD74 scFV interaction shown by the lowest HADDOCK score as a function of RMSD. The blue cluster was picked for further in silico mutagenesis. B Visualization of CD74-anti-CD74 scFV interaction. Red: CD74 trimer; Blue: anti-CD74 scFV

Additional file 6 of A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Additional file 6: Figure S6. No significant change in the body weights of the 74bbz CAR-T cells-treated mice was observed. The body weights of the mice treated UTT, 19bbz CAR-T and 74bbz CAR-T cells (n = 10 per group) were monitored until the mice reached ERC and plotted over time

Additional file 3 of A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Additional file 3: Figure S3. Expression of CD74 after activation on T cell and B cell. T cells and B cells isolated from PBMCs of 3 healthy blood donors were either untreated (red) or activated (blue) by CD3/CD28 soluble antibodies and IL-2 for T cells, and LPS (10 ng/mL)/ anti-IgM (10 µg/mL) for B cells. One representative of 3 healthy blood donors was shown

Additional file 4 of A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Additional file 4: Figure S4. Expression of CD74 on human CD34+ stem cells. Human umbilical cord blood mononuclear cells were stained with anti-CD34 and CD74 antibodies and analyzed by flow cytometry. One representative of 3 healthy cord blood donors was shown

Additional file 5 of A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Additional file 5: Figure S5. No significant depletion of circulating immune cells pre/post peak detection of 42105-74bbz CAR-T cells in a humanized mouse model. A Absolute cell numbers of B cells, monocytes, G-MDSC, M-MDSC and NK cells in humanized NSG mice on Day 3, 11 and 23 post UTT or 74bbz CAR-T engraftment. All human cells were identified by human CD45+. B: CD33−CD19+; Monocyte: LIN−CD45+CD11b+CD33+CD14+; G-MDSC: LIN−CD11b+CD33+CD14−HLA-DR−; M-MDSC: LIN−CD11b+CD33+CD14+HLA-DR−; NK: CD33−CD3−CD56+. Mice received either UTT cells (red, n = 5) and 42105-74bbz (blue, n = 7). Bars show the median cell number. B CD74 expression (blue) of B cells, monocytes, G-MDSC, M-MDSC and NK cells on Day 18 compared to isotype control (red). Data are from one mouse from the 42105-74bbz CAR-T cell treatment group